Cytokine Release Syndrome in the Immunotherapy of Hematological Malignancies: The Biology behind and Possible Clinical Consequences.

Second, IL-5 levels have been investigated only in a few studies, and one of these studies described an increase in IL5 levels for patients with advanced disease that reached borderline significance ( p = 0.017) and showed a large overlap between patients with advanced and less severe CRS [ 24 ] Third, as indicated in Table 1 the levels of Ang-1, Ang-2 and vascular endothelial growth factor (VEGF) are altered in patients advanced CRS; these effects alterations are not caused by a difference in

also in 370 other papers

It should be emphasized that even for several cytokines showing highly significant differences there may be a considerable overlap between these two patient subsets, and the cytokine showing the highest fold-increase can differ between patients [ 46 ].

also in 132,142 other papers